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A 52-year-old right-handed man presented for the evaluation of progressive emotional flattening, social withdrawal,
and loss of empathy. Prior to symptom onset, his wife of
21 years described him as “easy going, loving, kind, and
generous.” As symptoms progressed, the subject began to
alienate coworkers with unwelcome and persistent practical
jokes. These disinhibited behaviors were accompanied by
new, compulsive Internet usage. No language, visuospatial,
memory, or motor symptoms were reported.
Past medical history included chronic headaches and
multiple concussions but no seizures, psychiatric disorders, or drug use. He denied cutaneous, dental, or
renal abnormalities. His childhood development was
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unremarkable. He completed 13 years of formal education and worked in the upper echelons of management at a
professional firm.
The subject’s family history (Supplementary Fig. S1a)
was notable for a father with multiple concussions and
late-life seizures, alcoholism, impulsiveness, and poor
decision-making. An older sibling with left arm hemihypertrophy (Parkes-Weber Syndrome) was deceased after
post-operative stroke. A younger sibling developed epilepsy at age 19 and underwent frontal lobe resection surgery at age 43; this individual experienced progressive
difficulty with concentration and multitasking, qualifying
for a diagnosis of mild cognitive impairment (MCI) in the
executive domain.
On exam, the proband was 72 inches tall and weighed
220 lb (BMI of 29.8). Skin exam revealed ungual fibromas
and a shagreen patch. His neurological exam was normal
except for an expansive mood, intrusive commentary, and
jocularity verging on the inappropriate. Neuropsychological testing revealed impaired confrontational naming
with mild deficits in semantic knowledge. Visual episodic
memory, executive functioning, and information processing speed were also impaired. Other cognitive domains
were within normal limits for age. Deficits localized to the
right greater than left temporal and frontal lobes. Magnetic
resonance imaging (MRI) revealed corresponding areas of
atrophy and white matter lesions (Fig. 1a). Electroencephalogram (EEG) was negative for epileptiform activity.
The proband met criteria for probable behavioral variant
frontotemporal dementia (bvFTD), a sub-type of frontotemporal lobar degeneration (FTLD), based on early behavioral
disinhibition, loss of empathy, perseverative behaviors, neuropsychological profile, and MRI findings [12]. Given his
family history, he was screened for known genetic causes of
FTLD with no observed pathogenic variants. Therefore, the
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Fig. 1  Proband clinical MRI, novel TSC1 mutation, cell model of
TSC1/hamartin haploinsufficiency, and neuropathology of a TSC1
mutation carrier. a Magnetic resonance imaging (MRI) FLAIR
sequences revealed severe atrophy of the right anterior temporal
lobe, particularly the entorhinal/perirhinal cortices and inferior temporal gyrus, as well as the hippocampus and amygdala. There was
also involvement of the left anterior/mesial temporal lobe and the
bilateral frontal and right parietal lobes. T2/FLAIR hyperintensities are seen within the subcortical white matter, some of which
extended to the superolateral aspects of the lateral ventricles (arrowheads). These lesions can be seen in tuberous sclerosis or focal
cortical dysplasias as a transmantle sign. b Sanger sequencing con-

firmed a novel frameshift variant in the TSC1 gene (NM_000368.4:
c.62_63insTG: p. Arg22CysfsTer5) that segregated with the proband
and affected sibling. c Representative micrographs of the enlarged
cell body in the undifferentiated TSC1 heterozygous mutant SHSY5Y lines. Scale bars represent 50 microns. d Representative western blots showing decreased TSC1/hamartin and increased phophoP70S6Kthr389, total tau, and phospho-tau levels in retinoic acid differentiated TSC1 +/− SH-SY5Y cells. TDP-43 levels are unchanged. e–
g Fragment of frontal cortex resection from the proband’s sibling was
received and stained for hyperphosphorylated tau, revealing patchy
staining in neurons, glia, and surrounding neuropil. Scale bars represent 1000 (e), 250 (f), and 25 (g) microns

proband and his affected sibling underwent whole-exome
sequencing. Among variants identified, a novel frameshift
mutation in one allele of the TSC1 gene, predicted to result
in early termination of the TSC1/hamartin protein, was

shared by the proband and his younger sibling (Fig. 1b,
Supplementary Fig. S1b, c; Table S1).
TSC1/hamartin is an upstream inhibitor of mTOR,
which regulates cell growth and protein degradation [8].
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To determine the significance of the TSC1 loss of function variant, CRISPR/Cas9 genome editing [6] was used
to generate a cellular model of TSC1/hamartin deficiency
in SH-SY5Y cells, a human neuroblastoma cell line that
can be differentiated into neuronal-like cells [7] (Supplementary Fig. S2a). We confirmed that these lines exhibited
decreased TSC1/hamartin, increased cell size, and elevated
P70S6K phosphorylation, consistent with mTOR over
activity (Fig. 1c, Supplementary Fig. S2b, c). After retinoic acid (RA) differentiation, TSC1 +/− cells maintained
lower levels of TSC1/hamartin and increased mTOR activity. Interestingly, the RA-differentiated TSC1 +/− lines
accumulated phospho-tau and total tau. However, levels of
TDP-43, another protein that aggregates in FTLD [2], were
unchanged compared to control (Fig. 1d, Supplementary
Fig. S2d–h).
Histological samples were obtained from the partial
frontal lobe resection of the affected sibling, also a TSC1
mutation carrier. Similar to SH-SY5Y model of TSC1 heterozygosity, immunostaining of the resected tissue for phosphorylated tau revealed patchy neuropil staining as well as
diffuse cytoplasmic staining of scattered neurons and glia,
with variable intensity (Fig. 1e–g). No neurofibrillary tangles, Pick bodies, glial inclusions, or other features of an
inherited or sporadic tauopathy were observed. Sections
were also stained for TDP-43, phospho-TDP-43, amyloid
beta (Aβ), α-synuclein, and ubiquitin. Surprisingly, they
did not demonstrate elevated immunoreactivity for any
other neurodegenerative disease proteins (data not shown).
In this case report, we describe the first case of bvFTD
in an adult with sub-clinical tuberous sclerosis complex
(TSC) due to a novel TSC1 frameshift variant. Although
TSC has been called an “infantile tauopathy” [13], TSC1
mutations have not previously been implicated in age-associated neurodegenerative disease. This report, therefore,
potentially adds TSC1 to the list of genes that are implicated in both a juvenile-onset lysosomal storage disease
and adult-onset neurodegeneration. Others include GBA
and ATP13A2 in Parkinson’s disease, CTSD in Alzheimer’s disease, and PGRN in FTLD [10, 15]. The TSC1/
TSC2 complex normally inhibits mTOR activity, with loss
of function mutations resulting in overactive mTOR and
consequential increased protein synthesis and decreased
protein degradation [3, 8, 9]. Strikingly, the decreased protein degradation seems selective for tau, as evidenced from
both our cell-based and neuropathological data. This case
now suggests that with age, accumulated tau can precipitate neuron loss and neurodegeneration. It also raises the
intriguing possibility that tau metabolism is selectively regulated by the mTOR pathway. Our data suggest that TSC1
loss of heterozygosity, which is necessary for TSC-related
tumors [11], is not required for TSC1-related tau accumulation and neurodegeneration.
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Our findings could be highly significant to the care of
TSC patients. Many features of tuberous sclerosis associated neuropsychiatric disorders (TAND) [4, 5], including
obsessive behavior, attention deficits, altered eating, impulsivity, memory loss, and language dysfunction, overlap
with bvFTD criteria. Thus, these two clinical entities may
represent overlapping disorders precipitated by progressive
tau pathology. Additional sequencing of the TSC1/2 genes
in FTLD cohorts, use of new tau-based PET imaging, and
review of neuropathological specimens from older TSC
patients may further support the association between TSC,
TAND, and FTLD.
This study extends the relationship between mTOR and
tau metabolism [1, 16] to include a potential age-related
component. How does aging alter the TSC1/mTOR axis
to potentially contribute to the development of neurodegeneration? Why do tau and phospho-tau accumulate,
while related proteins that undergo chaperone mediated autophagy, such as TDP-43, do not? Do TSC2 mutations also link to age-related tauopathies? These questions
and others are stimulated by our report. In the meantime,
this study supports trials of rapamycin analogs which are
already underway for neurodegeneration [14], and moves
us towards a personalized medicine future in which subpopulations of tauopathy patients may be selectively
responsive to this therapeutic approach.
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